Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 1.00 |
| ▸ | NAAA | Q02083 | 1/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | DGKA | P23743 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11763013 | 1.00 | FAAH (1.00) | FAAHNAAACNR1CNR2HTR2C | |
| SCHEMBL7103980 | 0.98 | FAAH (0.96) | FAAHNAAACNR1CNR2HTR2C | |
| SCHEMBL7100995 | 0.92 | FAAH (0.86) | FAAHNAAACNR1CNR2HTR2C | |
| SCHEMBL9676495 | 0.88 | FAAH (0.79) | FAAHNAAAHTR2CEPHX1RAD52 | |
| SCHEMBL10525217 | 0.88 | FAAH (0.79) | FAAHNAAAHTR2CEPHX1RAD52 | |
| SCHEMBL28117615 | 0.86 | FAAH (0.75) | FAAHNAAAHTR2CEPHX1RAD52 | |
| SCHEMBL10901480 | 0.85 | FAAH (0.73) | FAAHNAAAHTR2CEPHX1RAD52 | |
| SCHEMBL8602516 | 0.85 | FAAH (0.73) | FAAHNAAAHTR2CEPHX1RAD52 | |
| SCHEMBL10604360 | 0.85 | FAAH (0.73) | FAAHNAAAHTR2CEPHX1RAD52 | |
| SCHEMBL10604950 | 0.85 | FAAH (0.73) | FAAHNAAAHTR2CEPHX1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1378566-B1 | Modified reductase from Penicillium citrinum and its encoding gene | SUMITOMO CHEMICAL CO (JP) | 2008-08-06 | — | — | EP | disclosed |
| EP-1213354-B1 | Process for producing optically active 4-halo-3-hydroxybutanoate | SUMITOMO CHEMICAL CO (JP) | 2007-05-30 | — | — | EP | disclosed |
| EP-1386961-B1 | Modified reductase and its gene and use thereof | SUMITOMO CHEMICAL CO (JP) | 2007-03-21 | — | — | EP | disclosed |
| US-7163814-B2 | Modified reductase and its gene, and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7135318-B2 | Modified reductase and its gene | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-11-14 | — | — | US | disclosed |
| US-20050191738-A1 | Modified reductase and its gene, and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2005-09-01 | — | — | US | disclosed |
| US-6884607-B2 | Process for producing optically active 4-halo-3-hydroxybutanoate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-04-26 | — | — | US | disclosed |
| US-20050019816-A1 | Process for producing optically active-4-halo-3-hydroxybutanoate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1201647-B1 | Process for producing 4-cyano-4oxobutanoate and 4-cyano-3-hydroxybutanoate | SUMITOMO CHEMICAL CO (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-20040091902-A1 | Modified reductase and its gene | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-05-13 | — | — | US | disclosed |
| EP-1386961-A2 | Modified reductase and its gene and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
| EP-1378566-A2 | Modified reductase from Penicillium citrinum and its encoding gene | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-01-07 | — | — | EP | disclosed |
| US-20030134402-A1 | Process for producing optically active 4-halo-3-hydroxybutanoate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-07-17 | — | — | US | disclosed |
| EP-1213354-A2 | Process for producing optically active 4-halo-3-hydroxybutanoate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-06-12 | — | — | EP | disclosed |
| EP-1201647-A2 | Process for producing 4-cyano-4oxobutanoate and 4-cyano-3-hydroxybutanoate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-05-02 | — | — | EP | disclosed |
| US-4933282-A | TREATING GAMMA-HALOACETONACETIC ACID ESTER WITH MICROORGANISM UNDER ANAEROBIC CONDITIONS | NIPPON GOHSEI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1990-06-12 | — | — | US | disclosed |
| US-4710468-A | FROM OPTICALLY ACTIVE SUBSTITUTED HYDROXYBUTYRIC ACID DERIVATIVES WITH OXIDOREDUCTASE | SIGMA-TAU INDUSTRIE PHARMACEUTICHE RIUNITE S.P.A. (IT) | 1987-12-01 | — | — | US | disclosed |
| US-4642290-A | OXIDOREDUCTASE ENZYMES FERMENTING 4-SUBSTITUTED-ACETOACETIC ESTERS OR AMIDES | SIH CHARLES J (US) | 1987-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134402-A1 | Process for producing optically active 4-halo-3-hydroxybutanoate | RNGTT, HMBS, POLB | FAAH 3017/4885NAAA 1165/4885CNR1 4414/4885 |
| US-20040091902-A1 | Modified reductase and its gene | BLVRB, DHFR, RRM2 | FAAH 3207/4885NAAA 1917/4885CNR1 3836/4885 |
| US-20050191738-A1 | Modified reductase and its gene, and use thereof | BLVRB, UPF1, GRHPR | FAAH 3202/4885NAAA 3436/4885CNR1 4035/4885 |
| US-20050019816-A1 | Process for producing optically active-4-halo-3-hydroxybutanoate | RNGTT, POLB, POLL | FAAH 2804/4885NAAA 1093/4885CNR1 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.